Replidyne Off to See Wall Street

Replidyne, Inc. (Nasdaq: proposed RDYN) intends to offer up to Wall St. 5 million shares priced between $14 and $16 in next weeks highly anticipated IPO. What makes me exceedingly bullish on this offering is that unlike many biotech IPO’s that transpire in the midst of Phase II or III and sometimes even during Phase I clinical trials, Replidyne has filed an NDA with the FDA for its lead product Orapem™, the pipeline is robust, partnerships with bigphamra are strong and, the management team lead by Ken Collins has proven to be outstanding.

GlobeImmune Initiates Phase II Study

GlobeImmune, Inc. announced the initiation of a Phase II clinical trial of GI-4000, for the treatment of early-stage pancreas cancer. GI-4000 is designed to activate the immune system against cancer cells containing a mutated protein called Ras that is found in 80-90% of pancreas tumors. In a recently completed Phase 1 study of end-stage pancreas and colorectal cancer patients, GI-4000 was generally well-tolerated across the full range of doses tested.

Read the Red Herring Top 100 Start-up Companies in America article on GlobeImmune here.